The Protein Labelling Market size in the Middle East & Africa was valued at USD 0.12 billion in 2022. It is further expected to grow at a CAGR of 6.18%, to reach USD 0.16 billion by 2027.
The protein labelling market in the MEA region is expected to be primarily driven by a strong trend of rising healthcare expenditures. Increased R&D spending and expansion in proteomics research are two more key causes. In addition, protein labelling is becoming more widely used in in vitro, in vivo, and biorthogonal labelling approaches, which will lead to market expansion. As a result, protein labelling is becoming increasingly popular. Protein labelling uses a short tag to prevent protein folding and function from being disrupted. Immunochemistry, fluorescence in situ hybridization (FISH), cell tracing, receptor tagging, and fluorescence spectroscopy are just a few of the applications for these fluorescent proteins. The market for Middle East Africa protein labelling is projected to develop even more in the future due to the expanding variety of applications.
Increased R&D expenditure for proteomics research aids protein analysis, driving demand for protein labelling methods. This increase in R&D funding has aided the proteomics field by expanding the usefulness of mass spectrometry, protein microarrays, and biochips in this sector. In addition, the use of labels in the detection and purification of proteins and diagnostic tests based on the detection of the presence of a specific protein has expanded dramatically due to the use of bioengineering.
Advancements also drive proteomics applications advancements in mass spectrometry processes and the miniaturization of biochips, which drive the market's organic revenue growth. The proteome content obtained from large-scale proteomics & genomics research is accelerating the development of novel biomarkers as R&D spending rises. Proteomics research is being supplemented by an increase in the number of medications in the R&D pipeline. Drug development, diagnostic, and therapeutic applications benefit from using contemporary molecular biology and bioengineering methods to increase understanding of functional mechanisms on a subcellular scale, both under pathologic and physiologic settings.
The market is projected to be hampered by issues with protein labelling procedures. Because of the disadvantages of labelled procedures, such as wet-lab complexity and flexibility, label-free techniques are favored. While label-free samples can be measured without any preparation, all labelling techniques require wet lab pre-treatment. The market's expansion is also being hampered by a scarcity of experienced personnel and insufficient applications of protein-labeling products.
Lack of specialists, limited uses of protein labelling goods, and high costs of reagents, kits, and other protein labelling services are potential challenges to the market expansion.
This research report on the Middle East and African Protein Labelling Market has been segmented and sub-segmented into the following categories:
South Africa leads the market because protein labelling study is expanding in this region due to its expanding range of applications. This country also has policies in place that encourage this type of growth. These policies encourage international companies to invest in the MEA. As a result, this country benefits from the presence of a large number of market players. Furthermore, the region's revenue growth is expected to be aided by the increased acceptance of customized medicine and genetic sequencing over the forecast period.
KEY MARKET PLAYERS:
A few of the notable companies in the MEA protein labelling market profiled in the report are Thermo Fisher Scientific, Inc., General Electric Company, Merck KGaA, Eurogentec S.A., PerkinElmer, Inc., F. Hoffmann-La Roche AG, New England Biolabs, Kaneka Corporation, Kirkegaard & Perry Laboratories, Promega Corporation, LI-COR, Inc. and SeraCare Life Sciences, Inc.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
188.8.131.52 Monoclonal Antibodies
184.108.40.206 Other Reagents
5.1.5 Y-o-Y Growth Analysis, By Product
5.1.6 Market Attractiveness Analysis, By Product
5.1.7 Market Share Analysis, By Product
5.2 Labeling Method
5.2.2 In vitro Labeling
220.127.116.11 Enzymatic Labeling
18.104.22.168 Dye-Based Labeling
22.214.171.124 Cotranslational Labeling
126.96.36.199 Site-Specific Labeling
188.8.131.52 Nanoparticle Labeling
5.2.3 In vivo Labeling
184.108.40.206 Photoreactive Labeling
220.127.116.11 Radioactive Labeling
5.2.4 Bioorthogonal Labeling
5.2.5 Y-o-Y Growth Analysis, By Type
5.2.6 Market Attractiveness Analysis, By Type
5.2.7 Market Share Analysis, By Type
5.3.2 Cell-Based Assay
5.3.3 Mass Spectroscopy
5.3.4 Fluorescence Microscopy
5.3.5 Immunological Technique
5.3.6 Protein Microarray
5.3.7 Y-o-Y Growth Analysis, By Application
5.3.8 Market Attractiveness Analysis, By Application
5.3.9 Market Share Analysis, By Application
5.4 End user
5.4.2 Y-o-Y Growth Analysis, By End user
5.4.2 Market Attractiveness Analysis, By End user
5.4.3 Market Share Analysis, By End user
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
18.104.22.168 By Geographical Area
22.214.171.124 By Product
126.96.36.199 By Labeling Method
188.8.131.52 By Application
184.108.40.206 By End user
6.1.4 Market Attractiveness Analysis
220.127.116.11 By Geographical Area
18.104.22.168 By Product
22.214.171.124 By Labeling Method
126.96.36.199 By Application
188.8.131.52 By End user
6.1.5 Market Share Analysis
184.108.40.206 By Geographical Area
220.127.116.11 By Product
18.104.22.168 By Labeling Method
22.214.171.124 By Application
126.96.36.199 By End user
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.1 Thermo Fisher Scientific, Inc.
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 General Electric Company
8.3 Merck KGaA
8.4 Eurogentec S.A.
8.5 PerkinElmer, Inc.
8.6 F. Hoffmann-La Roche AG
8.7 New England Biolabs
8.8 Kaneka Corporation
8.9 Kirkegaard & Perry Laboratories
8.10 Promega Corporation
8.11 LI-COR, Inc.
8.12 SeraCare Life Sciences, Inc.
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.